Your browser doesn't support javascript.
loading
Endocrine disorders among long-term survivors of childhood head and neck rhabdomyosarcoma.
Clement, S C; Schoot, R A; Slater, O; Chisholm, J C; Abela, C; Balm, A J M; van den Brekel, M W; Breunis, W B; Chang, Y C; Davila Fajardo, R; Dunaway, D; Gajdosova, E; Gaze, M N; Gupta, S; Hartley, B; Kremer, L C M; van Lennep, M; Levitt, G A; Mandeville, H C; Pieters, B R; Saeed, P; Smeele, L E; Strackee, S D; Ronckers, C M; Caron, H N; van Santen, H M; Merks, J H M.
Afiliación
  • Clement SC; Department of Pediatric Oncology, Emma Children's Hospital Academic Medical Center, Amsterdam, The Netherlands; Department of Pediatric Endocrinology, Wilhelmina Children's Hospital University Medical Center Utrecht, Utrecht, The Netherlands. Electronic address: s.c.clement@amc.uva.nl.
  • Schoot RA; Department of Pediatric Oncology, Emma Children's Hospital Academic Medical Center, Amsterdam, The Netherlands.
  • Slater O; Department of Pediatric Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.
  • Chisholm JC; Children and Young People's Department, Royal Marsden Hospital, Sutton, United Kingdom.
  • Abela C; Craniofacial Unit, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.
  • Balm AJM; Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Oral and Maxillofacial surgery, Academic Medical Center, Amsterdam, The Netherlands.
  • van den Brekel MW; Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Oral and Maxillofacial surgery, Academic Medical Center, Amsterdam, The Netherlands.
  • Breunis WB; Department of Pediatric Oncology, Emma Children's Hospital Academic Medical Center, Amsterdam, The Netherlands.
  • Chang YC; Department of Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
  • Davila Fajardo R; Department of Radiation Oncology, Academic Medical Center, Amsterdam, The Netherlands.
  • Dunaway D; Craniofacial Unit, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.
  • Gajdosova E; Department of Ophthalmology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.
  • Gaze MN; Department of Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
  • Gupta S; Department of Otorhinolaryngology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.
  • Hartley B; Department of Otorhinolaryngology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.
  • Kremer LCM; Department of Pediatric Oncology, Emma Children's Hospital Academic Medical Center, Amsterdam, The Netherlands.
  • van Lennep M; Department of Pediatric Oncology, Emma Children's Hospital Academic Medical Center, Amsterdam, The Netherlands.
  • Levitt GA; Department of Pediatric Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.
  • Mandeville HC; Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.
  • Pieters BR; Department of Radiation Oncology, Academic Medical Center, Amsterdam, The Netherlands.
  • Saeed P; Orbital center, Department of Ophthalmology, Academic Medical Center, Amsterdam, The Netherlands.
  • Smeele LE; Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Oral and Maxillofacial surgery, Academic Medical Center, Amsterdam, The Netherlands.
  • Strackee SD; Department of Plastic, Reconstructive and Hand Surgery, Academic Medical Center, Amsterdam, The Netherlands.
  • Ronckers CM; Department of Pediatric Oncology, Emma Children's Hospital Academic Medical Center, Amsterdam, The Netherlands.
  • Caron HN; Department of Pediatric Oncology, Emma Children's Hospital Academic Medical Center, Amsterdam, The Netherlands.
  • van Santen HM; Department of Pediatric Endocrinology, Wilhelmina Children's Hospital University Medical Center Utrecht, Utrecht, The Netherlands.
  • Merks JHM; Department of Pediatric Oncology, Emma Children's Hospital Academic Medical Center, Amsterdam, The Netherlands.
Eur J Cancer ; 54: 1-10, 2016 Feb.
Article en En | MEDLINE | ID: mdl-26707591
PURPOSE: Head and neck rhabdomyosarcoma (HNRMS) survivors are at increased risk of developing pituitary dysfunction as an adverse event of radiotherapy. Our aim was to investigate the frequency and risk factors for pituitary dysfunction in these survivors. Secondly, we aimed to compare the prevalence of pituitary dysfunction between survivors treated with external beam radiation therapy (EBRT) and survivors treated with the ablative surgery, moulage technique after loading brachytherapy, and surgical reconstruction (AMORE) procedure. METHODS: Eighty HNRMS survivors treated in London (EBRT based) and Amsterdam (AMORE based: AMORE if feasible, otherwise EBRT) in the period 1990-2010 and alive ≥ 2 years post-treatment were evaluated. Survivors were evaluated in multidisciplinary late-effects clinics, with measurement of linear growth, determination of thyroid function, and growth hormone parameters. Additional data, such as baseline characteristics, anthropometrics, pubertal stage, and the results of additional laboratory investigations, were retrieved from patient charts. RESULTS: Pituitary dysfunction was diagnosed in 24 in 80 (30%) survivors, after a median follow-up time of 11 years. Median time to develop pituitary dysfunction after HNRMS diagnosis was 3.0 years. Risk factors were EBRT-based therapy (odds ratio [OR] 2.06; 95% confidence interval [CI] 1.79-2.46), parameningeal tumour site (OR 1.83; 95% CI 1.60-2.17) and embryonal RMS histology (OR 1.49; 95% CI 1.19-1.90). CONCLUSIONS: Radiotherapy used for the treatment of HNRMS confers a significant risk of the development of pituitary dysfunction. AMORE-based treatment in children with HNRMS resulted in less pituitary dysfunction than treatment with conventional EBRT. Our findings underscore the importance of routine early endocrine follow-up in this specific population.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades de la Hipófisis / Traumatismos por Radiación / Rabdomiosarcoma / Braquiterapia / Irradiación Craneana / Sobrevivientes / Neoplasias de Cabeza y Cuello Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Europa Idioma: En Revista: Eur J Cancer Año: 2016 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades de la Hipófisis / Traumatismos por Radiación / Rabdomiosarcoma / Braquiterapia / Irradiación Craneana / Sobrevivientes / Neoplasias de Cabeza y Cuello Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Europa Idioma: En Revista: Eur J Cancer Año: 2016 Tipo del documento: Article Pais de publicación: Reino Unido